Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, Vaccinex, Inc. reported revenue of $1M, up 5.4% year over year. Operating margin was -3117.3% and net margin -3100.5%, on a free-cash-flow margin of -2696.8% with capital expenditure at 3.7% of revenue. Every figure is computed directly from VCNX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $1M | -3117.3% | -3100.5% |
| FY2023 | $1M | -4014.9% | -3552.8% |
| FY2022 | $0M | -7238.5% | -7205.5% |
| FY2021 | $1M | -2498.9% | -2486.7% |
| FY2020 | $1M | -4533.0% | -4616.2% |
How does VCNX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.